Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
نویسندگان
چکیده
Canada has a unique system of public drug coverage and reimbursement characterized by a centralized review agency that makes funding recommendations along with decentralized authority for delivering health care across 10 provinces and three territories. There has been a significant increase in price negotiation for new pharmaceuticals in the past 10 years, first by individual provinces and now through a collective price negotiation process called the "Pan-Canadian Pharmaceutical Alliance." As of February 2014, the Pan-Canadian Pharmaceutical Alliance has already completed 32 negotiations despite still being in a formative stage; it is anticipated that a formal process will be developed in the coming year. In this article, we describe the evolution of price negotiation in Canada and identify several opportunities for improvement of the current process, including the incorporation of economic considerations into price negotiation.
منابع مشابه
“Budget Impact Analyses”: a practical policy making tool for drug reimbursement decisions
Increasing accessibility and affordability of healthcare services has been considered as an important policy objective since the beginning of 1980s in Iran. However, current 60- 70% health care out-of-pocket payments create a barrier to an equal access to quality health services, especially in terms of new medicines which affects equity issues and "health" in Iran. Currently, health insurance o...
متن کامل“Budget Impact Analyses”: a practical policy making tool for drug reimbursement decisions
Increasing accessibility and affordability of healthcare services has been considered as an important policy objective since the beginning of 1980s in Iran. However, current 60- 70% health care out-of-pocket payments create a barrier to an equal access to quality health services, especially in terms of new medicines which affects equity issues and "health" in Iran. Currently, health insurance o...
متن کاملTargeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders
OBJECTIVES To address the uncertainty associated with procuring pharmaceutical products, product listing agreements (PLAs) are increasingly being used to support responsible funding decisions in Canada and elsewhere. These agreements typically involve financial-based rebating initiatives or, less frequently, outcome-based contracts. A qualitative survey was conducted to improve the understandin...
متن کاملComparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance
OBJECTIVES This study was conducted to determine whether establishment of the pan-Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug listing decisions across Canada. ANALYSIS AND RESULTS This study included drug indications that received a Common Drug Review or pan-Canadian Oncology Drug Review listing recommendation within 3 years before ('pre-PCPA era' g...
متن کاملUniversal Pharmacare in Canada: A Prescription for Equity in Healthcare
Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada remains the only developed nation with a publicly funded healthcare system that does not include universal coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to cover a specific sub-population for certain drugs. Altho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 8 شماره
صفحات -
تاریخ انتشار 2014